Key result
Thrombolytic agents such as early intravenous streptokinase significantly reduce in-hospital mortality in acute myocardial infarction, while newer agents aim for improved fibrin specificity.
Why the study?
Does thrombolytic therapy reduce in-hospital mortality in patients with acute myocardial infarction?
Does thrombolytic therapy reduce in-hospital mortality in patients with acute myocardial infarction?
This review highlights the evolution of thrombolytic therapy for acute myocardial infarction, noting the mortality benefits of early streptokinase and the development of more fibrin-specific agents.
No takes yet. Share an insight, caveat, or question.
Supports early thrombolysis in AMI; leaves open mortality benefit of newer fibrin-specific agents.
Collen et al. (1988) conducted a review in Acute myocardial infarction. Thrombolytic agents was evaluated. Thrombolytic agents such as early intravenous streptokinase significantly reduce in-hospital mortality in acute myocardial infarction, while newer agents aim for improved fibrin specificity.